메뉴 건너뛰기




Volumn 82, Issue 9, 2011, Pages 970-977

Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis

Author keywords

[No Author keywords available]

Indexed keywords

AMBENONIUM; CHOLINERGIC RECEPTOR ANTIBODY; INTERLEUKIN 2; PLACEBO; PREDNISOLONE; PYRIDOSTIGMINE; TACROLIMUS;

EID: 80051544886     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2011-300148     Document Type: Article
Times cited : (121)

References (25)
  • 1
    • 65749120107 scopus 로고    scopus 로고
    • Autoimmune disorders of the neuromuscular junction
    • Lang B, Vincent A. Autoimmune disorders of the neuromuscular junction. Curr Opin Pharmacol 2009;9:336-40.
    • (2009) Curr Opin Pharmacol , vol.9 , pp. 336-340
    • Lang, B.1    Vincent, A.2
  • 6
    • 2142643786 scopus 로고    scopus 로고
    • Oral glucocorticoid use is associated with an increased risk of fracture
    • DOI 10.1007/s00198-003-1548-3
    • Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 2004;15:323-8. (Pubitemid 38543952)
    • (2004) Osteoporosis International , vol.15 , Issue.4 , pp. 323-328
    • Steinbuch, M.1    Youket, T.E.2    Cohen, S.3
  • 9
    • 0031081658 scopus 로고    scopus 로고
    • FK506 prevents induction of rat experimental autoimmune myasthenia gravis
    • DOI 10.1006/jaut.1996.0111
    • Yoshikawa H, Iwasa K, Satoh K, et al. FK506 prevents induction of rat experimental autoimmune myasthenia gravis. J Autoimmun 1997;10:11-16. (Pubitemid 27110303)
    • (1997) Journal of Autoimmunity , vol.10 , Issue.1 , pp. 11-16
    • Yoshikawa, H.1    Iwasa, K.2    Satoh, K.3    Takamori, M.4
  • 13
    • 20844451899 scopus 로고    scopus 로고
    • Efficacy of low-dose FK506 in the treatment of myasthenia gravis - A randomized pilot study
    • DOI 10.1159/000085833
    • Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of low-dose FK506 in the treatment of Myasthenia gravis - a randomized pilot study. Eur Neurol 2005;53:146-50. (Pubitemid 40864306)
    • (2005) European Neurology , vol.53 , Issue.3 , pp. 146-150
    • Nagane, Y.1    Utsugisawa, K.2    Obara, D.3    Kondoh, R.4    Terayama, Y.5
  • 15
    • 0034641222 scopus 로고    scopus 로고
    • Myasthenia gravis: Recommendations for clinical research standards
    • Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America
    • Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
    • (2000) Neurology , vol.55 , pp. 16-23
    • Jaretzki III, A.1    Barohn, R.J.2    Ernstoff, R.M.3
  • 16
    • 0020513595 scopus 로고
    • Myasthenia gravis: Long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity
    • Besinger UA, Toyka KV, Homberg M, et al. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983;33:1316-21. (Pubitemid 13021194)
    • (1983) Neurology , vol.33 , Issue.10 , pp. 1316-1321
    • Besinger, U.A.1    Toyka, K.V.2    Homberg, M.3
  • 17
    • 44949109211 scopus 로고    scopus 로고
    • Steroids and immunosuppressant drugs in myasthenia gravis
    • DOI 10.1038/ncpneuro0810, PII NCPNEURO0810
    • Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol 2008;4:317-27. (Pubitemid 351803614)
    • (2008) Nature Clinical Practice Neurology , vol.4 , Issue.6 , pp. 317-327
    • Sathasivam, S.1
  • 19
    • 0025776560 scopus 로고
    • The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1
    • Banerji SS, Parsons JN, Tocci MJ. The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. Mol Cell Biol 1991;11:4074-87. (Pubitemid 21895797)
    • (1991) Molecular and Cellular Biology , vol.11 , Issue.8 , pp. 4074-4087
    • Banerji, S.S.1    Parsons, J.N.2    Tocci, M.J.3
  • 20
    • 0032125633 scopus 로고    scopus 로고
    • Dexamethasone and triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, rapamycin and their analogues, as well as by other P-glycoprotein ligands
    • DOI 10.1016/S0960-0760(98)00008-9, PII S0960076098000089
    • Marsaud V, Mercier-Bodard C, Fortin D, et al. Dexamethasone and triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, rapamycin and their analogues, as well as by other P-glycoprotein ligands. J Steroid Biochem Mol Biol 1998;66:11-25. (Pubitemid 28335451)
    • (1998) Journal of Steroid Biochemistry and Molecular Biology , vol.66 , Issue.1-2 , pp. 11-25
    • Marsaud, V.1    Mercier-Bodard, C.2    Fortin, D.3    Le, B.S.4    Renoir, J.-M.5
  • 21
    • 13544267438 scopus 로고    scopus 로고
    • Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506
    • DOI 10.1021/bi048503v
    • Davies TH, Ning YM, Sanchez ER. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 2005;44:2030-8. (Pubitemid 40223631)
    • (2005) Biochemistry , vol.44 , Issue.6 , pp. 2030-2038
    • Davies, T.H.1    Ning, Y.-M.2    Sanchez, E.R.3
  • 22
    • 33846966655 scopus 로고    scopus 로고
    • P-glycoprotein function in peripheral blood mononuclear cells of myasthenia gravis patients treated with tacrolimus
    • Tanaka S, Hirano T, Saito T, et al. P-glycoprotein function in peripheral blood mononuclear cells of myasthenia gravis patients treated with tacrolimus. Biol Pharm Bull 2007;30:291-6.
    • (2007) Biol Pharm Bull , vol.30 , pp. 291-296
    • Tanaka, S.1    Hirano, T.2    Saito, T.3
  • 23
    • 0029085326 scopus 로고
    • FK506 augments activation-induced programmed cell death of T lymphocytes in vivo
    • Migita K, Eguchi K, Kawabe Y, et al. FK506 augments activation-induced programmed cell death of T lymphocytes in vivo. J Clin Invest 1995;96:727-32.
    • (1995) J Clin Invest , vol.96 , pp. 727-732
    • Migita, K.1    Eguchi, K.2    Kawabe, Y.3
  • 25
    • 41949099206 scopus 로고    scopus 로고
    • Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis
    • Furukawa Y, Yoshikawa H, Iwasa K, et al. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. J Neuroimmunol 2008;195:108-15.
    • (2008) J Neuroimmunol , vol.195 , pp. 108-115
    • Furukawa, Y.1    Yoshikawa, H.2    Iwasa, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.